

Katja K H Aben

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2497241/publications.pdf>

Version: 2024-02-01

160
papers

24,685
citations

28274

55
h-index

7348

152
g-index

171
all docs

171
docs citations

171
times ranked

31048
citing authors

#	ARTICLE	IF	CITATIONS
1	Interlaboratory Gleason grading variation affects treatment: a Dutch historic cohort study in 30 509 patients with prostate cancer. <i>Journal of Clinical Pathology</i> , 2023, 76, 690-697.	2.0	2
2	Predictors of surgical treatment burden, outcomes, and overall survival in older adults with basal cell carcinoma: Results from the prospective, multicenter BATO cohort. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 1010-1019.	1.2	9
3	Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the Netherlands. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 43-52.	1.9	3
4	Skeletal muscle radiodensity and visceral adipose tissue index are associated with survival in renal cell cancer " A multicenter population-based cohort study. <i>Clinical Nutrition</i> , 2022, 41, 131-143.	5.0	11
5	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. <i>European Journal of Human Genetics</i> , 2022, 30, 349-362.	2.8	23
6	Using Explainable Machine Learning to Explore the Impact of Synoptic Reporting on Prostate Cancer. <i>Algorithms</i> , 2022, 15, 49.	2.1	4
7	Non-metastatic muscle-invasive bladder cancer: the role of age in receiving treatment with curative intent. <i>BJU International</i> , 2022, 130, 764-775.	2.5	3
8	Impact of the COVID-19 outbreak on prostate cancer care in the Netherlands. <i>Cancer Treatment and Research Communications</i> , 2022, 31, 100553.	1.7	11
9	The impact of the COVID-19 pandemic on bladder cancer care in the Netherlands. <i>Bladder Cancer</i> , 2022, , 1-17.	0.4	2
10	Evidence or Prejudice? Critical Re-Analysis of Randomized Controlled Trials Comparing Overall Survival After Cisplatin Versus Carboplatin-Based Regimens in Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e346-e352.	1.9	5
11	Sex differences in treatment patterns for non-advanced muscle-invasive bladder cancer: a descriptive analysis of 3484 patients of the Netherlands Cancer Registry. <i>World Journal of Urology</i> , 2022, 40, 2275-2281.	2.2	7
12	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 217-228.	2.5	12
13	Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry. <i>European Urology Focus</i> , 2021, 7, 788-796.	3.1	1
14	Variation in the Prescription of Androgen Deprivation Therapy in Intermediate- and High-risk Prostate Cancer Patients Treated with Radiotherapy in the Netherlands, and Adherence to European Association of Urology Guidelines: A Population-based Study. <i>European Urology Focus</i> , 2021, 7, 332-339.	3.1	6
15	Hospital volume is associated with postoperative mortality after radical cystectomy for treatment of bladder cancer. <i>BJU International</i> , 2021, 128, 511-518.	2.5	4
16	Rising incidence rates and unaltered survival rates for primary upper urinary tract urothelial carcinoma: a Dutch population-based study from 1993 to 2017. <i>BJU International</i> , 2021, 128, 343-351.	2.5	23
17	Intermediate-term survival of robot-assisted versus open radical cystectomy for muscle-invasive and high-risk non-muscle invasive bladder cancer in The Netherlands. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 40, 60.e1-60.e1.	1.6	4
18	Validation and reliability of the Dutch version of the EORTC QLQ-NMIBC24 Questionnaire Module for patients with non-muscle-invasive bladder cancer. <i>Journal of Patient-Reported Outcomes</i> , 2021, 5, 96.	1.9	5

#	ARTICLE	IF	CITATIONS
19	Guideline adherence for the surgical treatment of T1 renal tumours correlates with hospital volume: an analysis from the British Association of Urological Surgeons Nephrectomy Audit. <i>BJU International</i> , 2020, 125, 73-81.	2.5	19
20	Imaging and T Category for Prostate Cancer in the 8th Edition of the Union for International Cancer Control TNM Classification. <i>European Urology Oncology</i> , 2020, 3, 563-564.	5.4	7
21	The global burden of urinary bladder cancer: an update. <i>World Journal of Urology</i> , 2020, 38, 1895-1904.	2.2	504
22	Incidence, Survival, and Mortality Trends of Cancers Diagnosed in Adolescents and Young Adults (15â€“39 Years): A Population-Based Study in The Netherlands 1990â€“2016. <i>Cancers</i> , 2020, 12, 3421.	3.7	43
23	Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer. <i>Future Oncology</i> , 2020, 16, 1371-1384.	2.4	25
24	Radical prostatectomy versus deferred treatment for localised prostate cancer. <i>The Cochrane Library</i> , 2020, 6, CD006590.	2.8	23
25	No clear associations of adult BMI and diabetes mellitus with non-muscle invasive bladder cancer recurrence and progression. <i>PLoS ONE</i> , 2020, 15, e0229384.	2.5	12
26	Analysis of 105.000 patients with cancer: have they been discussed in oncologic multidisciplinary team meetings? A nationwide population-based study in the Netherlands. <i>European Journal of Cancer</i> , 2019, 121, 85-93.	2.8	16
27	Bladder cancer survival: Women only fare worse in the first two years after diagnosis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 853-861.	1.6	14
28	Oneâ€“carbon metabolism biomarkers and risk of urothelial cell carcinoma in the European prospective investigation into cancer and nutrition. <i>International Journal of Cancer</i> , 2019, 145, 2349-2359.	5.1	6
29	The UroLife study: protocol for a Dutch prospective cohort on lifestyle habits in relation to non-muscle-invasive bladder cancer prognosis and health-related quality of life. <i>BMJ Open</i> , 2019, 9, e030396.	1.9	13
30	Nationwide treatment patterns and survival of older patients with prostate cancer. <i>Journal of Geriatric Oncology</i> , 2019, 10, 252-258.	1.0	19
31	Immediate treatment vs. active-surveillance in very-low-risk prostate cancer: the role of patient-, tumour-, and hospital-related factors. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 337-343.	3.9	3
32	Guideline of guidelines: primary monotherapies for localised or locally advanced prostate cancer. <i>BJU International</i> , 2018, 122, 535-548.	2.5	19
33	Intravesical Radiofrequency-Induced Chemohyperthermia for Carcinoma in Situ of the Urinary Bladder: A Retrospective Multicentre Study. <i>Bladder Cancer</i> , 2018, 4, 365-376.	0.4	22
34	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. <i>PLoS ONE</i> , 2018, 13, e0197561.	2.5	9
35	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2473.	4.1	3
36	Smoking intensity and bladder cancer aggressiveness at diagnosis. <i>PLoS ONE</i> , 2018, 13, e0194039.	2.5	29

#	ARTICLE	IF	CITATIONS
37	Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. <i>Nature Genetics</i> , 2018, 50, 26-41.	21.4	286
38	Rare and low-frequency coding variants alter human adult height. <i>Nature</i> , 2017, 542, 186-190.	27.8	544
39	Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases. <i>JAMA Oncology</i> , 2017, 3, 636.	7.1	376
40	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	21.4	356
41	PD47-05 ELDERLY PROSTATE CANCER PATIENTS HAVE A WORSE PROGNOSIS THAN YOUNGER PATIENTS: A POPULATION-BASED STUDY IN THE NETHERLANDS.. <i>Journal of Urology</i> , 2017, 197, .	0.4	0
42	Risk factors for second primary melanoma among Dutch patients with melanoma. <i>British Journal of Dermatology</i> , 2017, 176, 971-978.	1.5	30
43	The Epidemiology and Clinicopathological Features of Basal Cell Carcinoma in Patients 80 Years and Older. <i>JAMA Dermatology</i> , 2017, 153, 71.	4.1	38
44	Incidence and survival trends of cancers diagnosed in young adults (20-39 years): A population-based study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1567-1567.	1.6	1
45	Independent Replication of Published Germline Polymorphisms Associated with Urinary Bladder Cancer Prognosis and Treatment Response. <i>Bladder Cancer</i> , 2016, 2, 77-89.	0.4	24
46	<i>PALB2</i>,<i>CHEK2</i>and<i>ATM</i>rare variants and cancer risk: data from COGS. <i>Journal of Medical Genetics</i> , 2016, 53, 800-811.	3.2	174
47	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. <i>Human Genetics</i> , 2016, 135, 741-756.	3.8	19
48	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016, 45, 1619-1630.	1.9	111
49	Genetic Risk Can Be Decreased: Quitting Smoking Decreases and Delays Lung Cancer for Smokers With High and Low CHRNA5 Risk Genotypes “ A Meta-Analysis. <i>EBioMedicine</i> , 2016, 11, 219-226.	6.1	40
50	Adherence to guideline recommendations for management of clinical T1 renal cancers in the Netherlands: a population-based study. <i>World Journal of Urology</i> , 2016, 34, 1053-1060.	2.2	13
51	The clinical phenotype of hereditary versus sporadic prostate cancer: HPC definition revisited. <i>Prostate</i> , 2016, 76, 897-904.	2.3	8
52	Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer“Results of a nationwide population-based study. <i>European Journal of Cancer</i> , 2016, 69, 1-8.	2.8	39
53	The effect of the time interval between diagnosis of muscle-invasive bladder cancer and radical cystectomy on staging and survival: A Netherlands Cancer Registry analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 166.e1-166.e6.	1.6	39
54	Insertion of an SVA-E retrotransposon into the<i>CASP8</i>gene is associated with protection against prostate cancer. <i>Human Molecular Genetics</i> , 2016, 25, 1008-1018.	2.9	22

#	ARTICLE	IF	CITATIONS
55	Perioperative treatment and radical cystectomy for bladder cancer – a population based trend analysis of 10,338 patients in the Netherlands. <i>European Journal of Cancer</i> , 2016, 54, 18-26.	2.8	44
56	Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. <i>Human Molecular Genetics</i> , 2016, 25, 1203-1214.	2.9	38
57	Cardiac monitoring during adjuvant trastuzumab therapy: Guideline adherence in clinical practice. <i>Acta Oncologica</i> , 2016, 55, 423-429.	1.8	12
58	Evidence of a genetic link between endometriosis and ovarian cancer. <i>Fertility and Sterility</i> , 2016, 105, 35-43.e10.	1.0	37
59	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016, 141, 386-401.	1.4	18
60	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. <i>Oncotarget</i> , 2016, 7, 69097-69110.	1.8	5
61	MP65-10 DELAYED RADICAL CYSTECTOMY IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER: A NATIONWIDE ANALYSIS. <i>Journal of Urology</i> , 2015, 193, .	0.4	0
62	Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. <i>Genetic Epidemiology</i> , 2015, 39, 689-697.	1.3	22
63	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. <i>PLoS ONE</i> , 2015, 10, e0128106.	2.5	44
64	Known susceptibility SNPs for sporadic prostate cancer show a similar association with –hereditary– prostate cancer. <i>Prostate</i> , 2015, 75, 474-483.	2.3	12
65	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015, 47, 164-171.	21.4	221
66	Germline deletions in the tumour suppressor gene <i>FOCAD</i> are associated with polyposis and colorectal cancer development. <i>Journal of Pathology</i> , 2015, 236, 155-164.	4.5	28
67	Genome-wide significant risk associations for mucinous ovarian carcinoma. <i>Nature Genetics</i> , 2015, 47, 888-897.	21.4	78
68	Network-Based Integration of GWAS and Gene Expression Identifies a <i>HOX</i> -Centric Network Associated with Serous Ovarian Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1574-1584.	2.5	28
69	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. <i>Gynecologic Oncology</i> , 2015, 136, 542-548.	1.4	15
70	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. <i>Nature Communications</i> , 2015, 6, 8234.	12.8	63
71	Associated Links Among Smoking, Chronic Obstructive Pulmonary Disease, and Small Cell Lung Cancer: A Pooled Analysis in the International Lung Cancer Consortium. <i>EBioMedicine</i> , 2015, 2, 1677-1685.	6.1	49
72	Common variants at the <i>CHEK2</i> gene locus and risk of epithelial ovarian cancer. <i>Carcinogenesis</i> , 2015, 36, 1341-1353.	2.8	24

#	ARTICLE	IF	CITATIONS
73	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. <i>Human Molecular Genetics</i> , 2015, 24, 5955-5964.	2.9	68
74	Recurrent urinary tract infection and risk of bladder cancer in the Nijmegen bladder cancer study. <i>British Journal of Cancer</i> , 2015, 112, 594-600.	6.4	87
75	Dermatological exposure to coal tar and bladder cancer risk: A case-control study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 20.e19-20.e22.	1.6	16
76	The prognostic value of family history among patients with urinary bladder cancer. <i>International Journal of Cancer</i> , 2015, 136, 1117-1124.	5.1	16
77	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). <i>Journal of Genetics and Genome Research</i> , 2015, 2, .	0.3	25
78	International comparison of treatment and outcome in older patients with muscle-invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20517-e20517.	1.6	0
79	New insights into the aetiology of scrotal cancer, a nationwide case-control study in the Netherlands. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 65-71.	2.4	8
80	Reproducibility of self-reported melanoma risk factors in melanoma patients. <i>Melanoma Research</i> , 2014, 24, 592-601.	1.2	8
81	Risk of Ovarian Cancer and the NF- κ B Pathway: Genetic Association with <i>IL1A</i> and <i>TNFSF10</i> . <i>Cancer Research</i> , 2014, 74, 852-861.	0.9	48
82	Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. <i>Human Genetics</i> , 2014, 133, 481-497.	3.8	23
83	Self-reported acne is not associated with prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 941-945.	1.6	3
84	Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. <i>Molecular Nutrition and Food Research</i> , 2014, 58, 2023-2035.	3.3	16
85	Impact of mitotic activity on the pathological substaging of pT1 cutaneous melanoma. <i>British Journal of Dermatology</i> , 2014, 170, 874-877.	1.5	8
86	Genome-wide association study yields variants at 20p12.2 that associate with urinary bladder cancer. <i>Human Molecular Genetics</i> , 2014, 23, 5545-5557.	2.9	46
87	Limited role for histopathological examination of re-excision specimens of completely excised melanomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 465, 225-231.	2.8	2
88	Prognostic Relevance of Urinary Bladder Cancer Susceptibility Loci. <i>PLoS ONE</i> , 2014, 9, e89164.	2.5	20
89	Survival of adolescents and young adults (AYAs) with skeletal Ewing sarcoma: A Dutch population-based study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10530-10530.	1.6	0
90	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 362-370.	21.4	326

#	ARTICLE	IF	CITATIONS
91	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	21.4	493
92	Melanoma of unknown primary origin: A population-based study in the Netherlands. <i>European Journal of Cancer</i> , 2013, 49, 676-683.	2.8	43
93	A variant in FTO shows association with melanoma risk not due to BMI. <i>Nature Genetics</i> , 2013, 45, 428-432.	21.4	111
94	A common variant at 8q24.21 is associated with renal cell cancer. <i>Nature Communications</i> , 2013, 4, 2776.	12.8	56
95	Combined and Interactive Effects of Environmental and GWAS-Identified Risk Factors in Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 880-890.	2.5	54
96	Plasma carotenoids and vitamin C concentrations and risk of urothelial cell carcinoma in the European Prospective Investigation into Cancer and Nutrition. <i>American Journal of Clinical Nutrition</i> , 2012, 96, 902-910.	4.7	43
97	The effect of the ATG16L1 Thr300Ala polymorphism on susceptibility and outcome of patients with epithelial cell-derived thyroid carcinoma. <i>Endocrine-Related Cancer</i> , 2012, 19, L15-L18.	3.1	34
98	A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer. <i>Nature Genetics</i> , 2012, 44, 1326-1329.	21.4	178
99	Pattern of follow-up care and early relapse detection in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 859-868.	2.5	40
100	DNA adducts in skin biopsies and 1-hydroxypyrene in urine of psoriasis patients and healthy volunteers following treatment with coal tar. <i>Toxicology Letters</i> , 2012, 213, 39-44.	0.8	14
101	Discrepancy between clinical staging through bimanual palpation and pathological staging after cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 247-251.	1.6	39
102	Successful centralisation of patients with vulvar carcinoma: A population-based study in The Netherlands. <i>European Journal of Cancer</i> , 2012, 48, 1997-2003.	2.8	16
103	Modest improvement in 20years of kidney cancer care in the Netherlands. <i>European Journal of Cancer</i> , 2012, 48, 1822-1830.	2.8	8
104	Fruit and vegetable consumption and risk of aggressive and non-aggressive urothelial cell carcinomas in the European Prospective Investigation into Cancer and Nutrition. <i>European Journal of Cancer</i> , 2012, 48, 3267-3277.	2.8	26
105	Personal hair dye use and the risk of bladder cancer: a case-control study from The Netherlands. <i>Cancer Causes and Control</i> , 2012, 23, 1139-1148.	1.8	33
106	Mutations in BRIP1 confer high risk of ovarian cancer. <i>Nature Genetics</i> , 2011, 43, 1104-1107.	21.4	338
107	A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. <i>Nature Genetics</i> , 2011, 43, 1098-1103.	21.4	251
108	Incidence and prognosis of parathyroid gland carcinoma: A population-based study in The Netherlands estimating the preoperative diagnosis. <i>American Journal of Surgery</i> , 2011, 202, 590-597.	1.8	56

#	ARTICLE	IF	CITATIONS
109	Functional Polymorphisms in the TERT Promoter Are Associated with Risk of Serous Epithelial Ovarian and Breast Cancers. PLoS ONE, 2011, 6, e24987.	2.5	48
110	Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nature Genetics, 2011, 43, 60-65.	21.4	220
111	Prognostic Factors for Survival in Patients With Recurrence of Muscle Invasive Bladder Cancer After Treatment With Curative Intent. Clinical Genitourinary Cancer, 2011, 9, 14-21.	1.9	14
112	Prevalence of multiple malignancies in the Netherlands in 2007. International Journal of Cancer, 2011, 128, 1659-1667.	5.1	45
113	Fluid intake and the risk of urothelial cell carcinomas in the European Prospective Investigation into Cancer and Nutrition (EPIC). International Journal of Cancer, 2011, 128, 2695-2708.	5.1	58
114	Sequence variants at CYP1A1 and CYP1A2 and AHR associate with coffee consumption. Human Molecular Genetics, 2011, 20, 2071-2077.	2.9	114
115	Genome-Wide Significant Association Between a Sequence Variant at 15q15.2 and Lung Cancer Risk. Cancer Research, 2011, 71, 1356-1361.	0.9	26
116	European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. Human Molecular Genetics, 2011, 20, 4268-4281.	2.9	134
117	No Increased Risk of Cancer after Coal Tar Treatment in Patients with Psoriasis or Eczema. Journal of Investigative Dermatology, 2010, 130, 953-961.	0.7	86
118	Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature, 2010, 467, 832-838.	27.8	1,789
119	A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nature Genetics, 2010, 42, 415-419.	21.4	169
120	Sequence variants at CHRNA6 and CYP2A6 affect smoking behavior. Nature Genetics, 2010, 42, 448-453.	21.4	649
121	Genome-wide association study identifies a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysm. Nature Genetics, 2010, 42, 692-697.	21.4	181
122	Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nature Genetics, 2010, 42, 880-884.	21.4	235
123	A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nature Genetics, 2010, 42, 874-879.	21.4	321
124	Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nature Genetics, 2010, 42, 937-948.	21.4	2,634
125	A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nature Genetics, 2010, 42, 978-984.	21.4	493
126	Genetic Correction of PSA Values Using Sequence Variants Associated with PSA Levels. Science Translational Medicine, 2010, 2, 62ra92.	12.4	140

#	ARTICLE	IF	CITATIONS
127	1719 PROGNOSTIC FACTORS FOR SURVIVAL IN PATIENTS WITH RECURRENCE OF MUSCLE INVASIVE BLADDER CANCER AFTER TREATMENT WITH CURATIVE INTENT. <i>Journal of Urology</i> , 2010, 183, .	0.4	1
128	Ancestry-Shift Refinement Mapping of the C6orf97-ESR1 Breast Cancer Susceptibility Locus. <i>PLoS Genetics</i> , 2010, 6, e1001029.	3.5	82
129	The present and future burden of urinary bladder cancer in the world. <i>World Journal of Urology</i> , 2009, 27, 289-293.	2.2	772
130	Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. <i>Nature Genetics</i> , 2009, 41, 18-24.	21.4	1,247
131	Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. <i>Nature Genetics</i> , 2009, 41, 221-227.	21.4	572
132	Genome-wide association study identifies sequence variants on 6q21 associated with age at menarche. <i>Nature Genetics</i> , 2009, 41, 734-738.	21.4	199
133	New common variants affecting susceptibility to basal cell carcinoma. <i>Nature Genetics</i> , 2009, 41, 909-914.	21.4	303
134	Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. <i>Nature Genetics</i> , 2009, 41, 991-995.	21.4	321
135	Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. <i>Nature Genetics</i> , 2009, 41, 1122-1126.	21.4	313
136	Expert review remains important in the histopathological diagnosis of cutaneous melanocytic lesions. <i>Histopathology</i> , 2008, 52, 139-146.	2.9	55
137	Trends in incidence and mortality of thyroid carcinoma in The Netherlands between 1989 and 2003: Correlation with thyroid fine-needle aspiration cytology and thyroid surgery. <i>International Journal of Cancer</i> , 2008, 123, 1681-1684.	5.1	43
138	A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. <i>Nature</i> , 2008, 452, 638-642.	27.8	1,399
139	Many sequence variants affecting diversity of adult human height. <i>Nature Genetics</i> , 2008, 40, 609-615.	21.4	615
140	Common variants on chromosome 5p12 confer susceptibility to estrogen receptor- α positive breast cancer. <i>Nature Genetics</i> , 2008, 40, 703-706.	21.4	412
141	Two newly identified genetic determinants of pigmentation in Europeans. <i>Nature Genetics</i> , 2008, 40, 835-837.	21.4	331
142	Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. <i>Nature Genetics</i> , 2008, 40, 1307-1312.	21.4	377
143	Male-pattern baldness susceptibility locus at 20p11. <i>Nature Genetics</i> , 2008, 40, 1282-1284.	21.4	118
144	Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. <i>Nature Genetics</i> , 2008, 40, 281-283.	21.4	357

#	ARTICLE	IF	CITATIONS
145	Coal tar in dermatology. <i>Journal of Dermatological Treatment</i> , 2007, 18, 329-334.	2.2	38
146	Genetic determinants of hair, eye and skin pigmentation in Europeans. <i>Nature Genetics</i> , 2007, 39, 1443-1452.	21.4	659
147	Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. <i>Nature Genetics</i> , 2007, 39, 631-637.	21.4	818
148	Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. <i>Nature Genetics</i> , 2007, 39, 977-983.	21.4	670
149	Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. <i>Nature Genetics</i> , 2007, 39, 865-869.	21.4	774
150	Treatment policy for psoriasis and eczema: a survey among dermatologists in the Netherlands and Belgian Flanders. <i>European Journal of Dermatology</i> , 2007, 17, 416-21.	0.6	11
151	Segregation analysis of urothelial cell carcinoma. <i>European Journal of Cancer</i> , 2006, 42, 1428-1433.	2.8	30
152	Site-specific familial aggregation of prostate cancer. <i>International Journal of Cancer</i> , 2004, 109, 611-617.	5.1	25
153	More Differences Between HNPCC-related and Sporadic Carcinomas From the Endometrium as Compared to the Colon. <i>American Journal of Surgical Pathology</i> , 2004, 28, 706-711.	3.7	62
154	Spouse controls in family case-control studies: a methodological consideration. <i>Familial Cancer</i> , 2003, 2, 101-108.	1.9	11
155	Familial aggregation of urothelial cell carcinoma. <i>International Journal of Cancer</i> , 2002, 98, 274-278.	5.1	106
156	Absence of karyotype abnormalities in patients with familial urothelial cell carcinoma. <i>Urology</i> , 2001, 57, 266-269.	1.0	5
157	A Germline Homozygote Deletion of the Glutathione-S-Transferase Mu1 Gene Predisposes to Bladder Cancer. <i>Urologia Internationalis</i> , 2000, 64, 134-138.	1.3	8
158	Gender differences in stage-adjusted bladder cancer survival. <i>Urology</i> , 2000, 55, 876-880.	1.0	197
159	Epidemiology of Bladder Cancer. <i>European Urology</i> , 1999, 36, 660-672.	1.9	42
160	Determination of serum liver tests during therapy with coumarin anticoagulants. <i>Journal of Hepatology</i> , 1999, 31, 778-779.	3.7	0